A New Drug Application (NDA) for CARDAMYST is currently being evaluated by the U.S. Food & Drug Administration (FDA) which has set a new Prescription Drug User Fee Act (PDFUA) target date of December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback